Infectious Diseases Market in the US 2015-2019

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.2.1 Market Penetration
06.2.2 Marketing Approvals
06.2.3 Patent Protection
06.2.4 Regulatory Designation
06.2.5 Orphan Drug Designation
06.2.6 WHO Recognition
06.2.7 Other Factors
06.3 Five Forces Analysis
07. Epidemiology
07.1 Viral Infections
07.2 Fungal Infections
07.3 Bacterial Infections
07.4 Parasitic Infections
08. Market Segmentation by Type of Drug
08.1 Anti-bacterial Drugs
08.1.1 Anti-bacterial Drugs Market in US
08.2 Anti-viral Drugs
08.2.1 Anti-viral Drugs Market in US
08.3 Anti-fungal Drugs
08.3.1 Anti-fungal Drugs Market in US
08.4 Anti-parasitic Drugs
08.4.1 Anti-parasitic Drugs Market in US
09. Market Segmentation by Route of Administration
09.1 Oral
09.2 Parenteral
09.3 Topical
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2014
17.2.1 Gilead Sciences
17.2.2 Johnson & Johnson
17.2.3 Merck
17.2.4 Pfizer
17.2.5 F. Hoffmann-La Roche
17.2.6 GlaxoSmithKline
17.3 Other and Future Prominent Vendors
18. Key Vendor Analysis
18.1 F. Hoffmann-La Roche Ltd.
18.1.1 Key Facts
18.1.2 Business Overview
18.1.3 Business Segmentation
18.1.4 Business Segmentation by Revenue 2012 and 2013
18.1.5 Sales by Geography
18.1.6 Business Strategy
18.1.7 Key Information
18.1.8 SWOT Analysis
18.2 Gilead Sciences
18.2.1 Key Facts
18.2.2 Business Overview
18.2.3 Geographical Segmentation by Revenue 2013
18.2.4 Recent Developments
18.2.5 SWOT Analysis
18.3 GlaxoSmithKline
18.3.1 Key Facts
18.3.2 Business Overview
18.3.3 Business Segmentation by Revenue 2014
18.3.4 Business Segmentation by Revenue 2013 and 2014
18.3.5 Geographical Segmentation by Revenue 2014
18.3.6 Business Strategy
18.3.7 Recent Developments
18.3.8 SWOT Analysis
18.4 Johnson & Johnson
18.4.1 Key Facts
18.4.2 Business Overview
18.4.3 Business Segmentation by Revenue 2014
18.4.4 Business Segmentation by Revenue 2013 and 2014
18.4.5 Geographical Segmentation by Revenue 2014
18.4.6 Business Strategy
18.4.7 Recent Developments
18.4.8 SWOT Analysis
18.5 Merck
18.5.1 Key Facts
18.5.2 Business Overview
18.5.3 Business Segmentation by Revenue 2013
18.5.4 Business Segmentation by Revenue 2012 and 2013
18.5.5 Sales by Geography
18.5.6 Business Strategy
18.5.7 Key Developments
18.5.8 SWOT Analysis
18.6 Pfizer
18.6.1 Key Facts
18.6.2 Business Overview
18.6.3 Business Segmentation by Revenue 2014
18.6.4 Business Segmentation by Revenue 2013 and 2014
18.6.5 Geographical Segmentation by Revenue 2014
18.6.6 Business Strategy
18.6.7 Key Developments
18.6.8 SWOT Analysis
19. Other Reports in this Series